Germany’s Expert Committee on Prescription, the SVA, has rejected applications to switch from Rx to OTC status erectile dysfunction drugs sildenafil (25mg) and tadalafil (10mg).
In doing so, it has gone against the wishes of the German Ministry of Health, the BMG, which in October last year announced to industry’s surprise that it would like to see the entire group of PDE-5 inhibitors switched to non-prescription status
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?